BACKGROUND: Alternative (M2) macrophage activation is associated with tumor development in many tumor types, including those in the lung. Herein the biological consequences of forcing classical (M1) or alternative (M2) macrophage activation on lung tumor development are examined. MATERIALS AND METHODS: Urethane-induced lung tumor multiplicity and size were compared in IFN-gamma(-/-) mice which lack M1 macrophage activation, IL-4Ralpha(-/-) mice which lack M2 macrophage activation, and wild-type BALB/cJ (background strain of the IFN-gamma(-/-) and IL-4Ralpha(-/-) mice) mice. Tumor-associated macrophage (TAM) and bone marrow-derived monocyte (BDMC) activation were each examined. RESULTS: The TAMs and BDMCs in the IFN-gamma(-/-) mice exhibited M2 activation, and their lung tumors were significantly larger than those in the wild-type mice. In contrast, urethane-treated IL-4Ralpha(-/-) mice, whose TAMs and BDMCs were M1 activated, developed smaller tumors than the wild-type mice. CONCLUSION: Altered innate immunity can diminish or accelerate lung tumor progression in response to defective cytokine signaling.
BACKGROUND: Alternative (M2) macrophage activation is associated with tumor development in many tumor types, including those in the lung. Herein the biological consequences of forcing classical (M1) or alternative (M2) macrophage activation on lung tumor development are examined. MATERIALS AND METHODS:Urethane-induced lung tumor multiplicity and size were compared in IFN-gamma(-/-) mice which lack M1 macrophage activation, IL-4Ralpha(-/-) mice which lack M2 macrophage activation, and wild-type BALB/cJ (background strain of the IFN-gamma(-/-) and IL-4Ralpha(-/-) mice) mice. Tumor-associated macrophage (TAM) and bone marrow-derived monocyte (BDMC) activation were each examined. RESULTS: The TAMs and BDMCs in the IFN-gamma(-/-) mice exhibited M2 activation, and their lung tumors were significantly larger than those in the wild-type mice. In contrast, urethane-treated IL-4Ralpha(-/-) mice, whose TAMs and BDMCs were M1 activated, developed smaller tumors than the wild-type mice. CONCLUSION: Altered innate immunity can diminish or accelerate lung tumor progression in response to defective cytokine signaling.
Authors: Toni M Robinson-Smith; Idit Isaacsohn; Carol A Mercer; Mingfu Zhou; Nico Van Rooijen; Nader Husseinzadeh; Molly M McFarland-Mancini; Angela F Drew Journal: Cancer Res Date: 2007-06-15 Impact factor: 12.701
Authors: Cesar E Ochoa; Seyedeh Golsar Mirabolfathinejad; Venado Ana Ruiz; Scott E Evans; Mihai Gagea; Christopher M Evans; Burton F Dickey; Seyed Javad Moghaddam Journal: Cancer Prev Res (Phila) Date: 2010-11-22
Authors: Rinat Zaynagetdinov; Taylor P Sherrill; Vasiliy V Polosukhin; Wei Han; Jamie A Ausborn; Allyson G McLoed; Frank B McMahon; Linda A Gleaves; Amber L Degryse; Georgios T Stathopoulos; Fiona E Yull; Timothy S Blackwell Journal: J Immunol Date: 2011-11-02 Impact factor: 5.422
Authors: Sergey V Kalish; Svetlana V Lyamina; Elena A Usanova; Eugenia B Manukhina; Nikolai P Larionov; Igor Y Malyshev Journal: Med Sci Monit Basic Res Date: 2015-10-16
Authors: Jason M Fritz; Meredith A Tennis; David J Orlicky; Hao Lin; Cynthia Ju; Elizabeth F Redente; Kevin S Choo; Taylor A Staab; Ronald J Bouchard; Daniel T Merrick; Alvin M Malkinson; Lori D Dwyer-Nield Journal: Front Immunol Date: 2014-11-25 Impact factor: 7.561
Authors: Thomas Hill; Ross S Osgood; Kalpana Velmurugan; Carla-Maria Alexander; Brad L Upham; Alison K Bauer Journal: J Mol Biomark Diagn Date: 2013-12-27
Authors: Sergey V Novitskiy; Rinat Zaynagetdinov; Georgii Vasiukov; Sergey Gutor; Wei Han; Ana Serezani; Anton Matafonov; Linda A Gleaves; Taylor P Sherrill; Vasiliy V Polosukhin; Timothy S Blackwell Journal: Oncotarget Date: 2019-12-17